Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Vaxart, Inc. (NASDAQ:VXRT) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.41 and traded as low as $0.32. Vaxart shares last traded at $0.3295, with a volume of 629,328 shares trading hands.

Vaxart Price Performance

The company’s 50 day moving average is $0.37 and its 200 day moving average is $0.41. The stock has a market cap of $75.44 million, a price-to-earnings ratio of -1.22 and a beta of 1.39.

Institutional Trading of Vaxart

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart during the first quarter worth about $31,000. Creative Planning acquired a new position in shares of Vaxart in the 2nd quarter valued at $33,000. Virtu Financial LLC acquired a new position in shares of Vaxart in the 1st quarter valued at $56,000. Invesco Ltd. boosted its holdings in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in shares of Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.